|
- Scheduled for Friday, January 4, 2019 at 9 AM ET - WESTLAKE VILLAGE, Calif., Dec. 27, 2018 (GLOBE NEWSWIRE) -- MannKind Corporation (MNKD) will host a conference call on Friday, January 4, 2019 to discuss Company developments at 9:00 AM (Eastern Time). Presenting from the Company will be its Chief Executive Officer, Michael Castagna. To participate in the live call by telephone, please dial (800) 263-0877 or (646) 828-8143 and use the participant passcode: 1338434. Those interested in listening to the conference call live via the Internet may do so by visiting the Company's website at http://www.mannkindcorp.com under News & Events. A telephone replay of the call will be accessible for approximately 14 days following completion of the call by dialing (844) 512-2921 or (412) 317-6671 and use the participant passcode: 1338434#. A replay will also be available on MannKind's website for 14 days. About MannKind Corporation MannKind Corporation (MNKD) focuses on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. MannKind is currently commercializing Afrezza\u00ae (insulin human) Inhalation Powder, the Company's first FDA-approved product and the only inhaled rapid-acting mealtime insulin in the United States, where it is available by prescription from pharmacies nationwide. MannKind is headquartered in Westlake Village, California, and has a state-of-the art manufacturing facility in Danbury, Connecticut. The Company also employs field sales and medical representatives across the U.S. |
|
| aus der Diskussion: | Mannkind, Game-Chancer in Sachen Diabetik? |
| Autor (Datum des Eintrages): | Magnetfeldfredy (27.12.18 15:20:21) |
| Beitrag: | 5,164 von 6,825 (ID:59514430) |
| Alle Angaben ohne Gewähr © wallstreetONLINE | |